Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the acquisition of Whitecap Biosciences, , enhancing its clinical-stage pipeline. Whitecap is developing two innovative therapies for glaucoma and geographic atrophy (GA). Whitecap Biosciences, founded in 2015, focuses on novel treatments for serious eye diseases, successfully completing Phase 2 trials for WB007 in glaucoma, a potent alpha-2 adrenergic agonist. Further trials are planned for both glaucoma and GA. Glaucoma, a progressive neurodegenerative disease, affects about four million people in the U.S. and is a leading cause of preventable blindness. GA, also known as advanced dry age-related macular degeneration, affects approximately one million people in the U.S. By joining Bausch + Lomb, Whitecap aims to develop its assets into effective treatments to improve visual outcomes.

Bausch + Lomb (NYSE/TSX: BLCO) has announced the commercial launch of enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union following CE Mark approval. The enVista Aspire combines Intermediate Optimized optics for broader depth of focus with the established enVista platform benefits.

The product features include glistening-free optic material and StableFlex Technology for controlled unfolding. The toric version offers treatment for astigmatism during cataract surgery with a +0.90 cylinder design and AccuSet haptic design for rotational stability.

The IOLs are indicated for primary implantation in adult patients for visual correction of aphakia following cataract lens removal, with the toric version specifically addressing corneal astigmatism. The device uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter.

Outcome Capital announces the successful acquisition of Elios Vision by Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, a developer of minimally invasive glaucoma surgery (MIGS) using excimer laser technology, has created the ELIOS™ procedure, an implant-free treatment designed to reduce intraocular pressure in glaucoma patients while minimizing risks associated with traditional surgeries.

The technology is currently CE-marked and available in the European Union, with FDA approval being sought this year. The procedure can be performed standalone or alongside cataract surgery, offering broader adoption potential due to its relative simplicity compared to implant-based MIGS. The acquisition strengthens Bausch + Lomb's position in the $2.5 billion glaucoma treatment market, addressing a condition that affects over 76 million people globally.

Bausch + Lomb (NYSE/TSX: BLCO) and Glaucoma Research Foundation (GRF) are launching their second annual 'Faces of Glaucoma' campaign during Glaucoma Awareness Month in January. The initiative aims to raise awareness about glaucoma, the second leading cause of blindness worldwide, by sharing diverse patient stories and educational resources.

The campaign highlights that approximately half of people with glaucoma are unaware they have the condition. As part of the initiative, Bausch + Lomb will match donations up to $20,000 for the fourth consecutive year to support GRF's research toward finding a cure.

The campaign emphasizes that while glaucoma is often associated with older individuals, it can affect anyone regardless of race, age, or gender. Early intervention, including prescription eye drops, can help slow the disease's progression, though there is currently no cure. Detection requires yearly comprehensive dilated eye exams by eye care professionals.

Bausch + Lomb (NYSE/TSX: BLCO) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's leadership team, including Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and Chief Medical Officer and Head of R&D Yehia Hashad, M.D., will deliver a company presentation on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

The global eye health company will provide a live webcast of the event, with an audio archive available afterward on their Investor Relations page at http://ir.bausch.com/investors/events-presentations.

Bausch + Lomb (NYSE/TSX: BLCO) has confirmed it is exploring a potential sale as one of several options to achieve complete separation from Bausch Health Companies Inc. The company's board of directors has authorized management and advisors to explore this possibility, though no transaction is guaranteed. This statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.

Bausch + Lomb (NYSE/TSX: BLCO) has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) using an excimer laser. The acquisition strengthens BLCO's glaucoma portfolio by introducing a differentiated treatment approach that can be performed alongside cataract surgery.

The ELIOS system offers a tissue-friendly, non-thermal laser-based procedure for glaucoma, which is expected to see a 47% prevalence increase from 2020 to 2040. The technology is currently CE marked and available in the European Union, with FDA approval pending. Over 19% of cataract surgery patients also have glaucoma or ocular hypertension, presenting an opportunity for concurrent treatment.

Bausch + Lomb (NYSE/TSX: BLCO) announced significant achievements in its recycling initiatives, with its ONE by ONE Recycling and Biotrue Eye Care Recycling programs collecting over 94 million units (569,743 pounds) of used contact lenses, eye care, and lens care materials in the United States. This recycling effort addresses a important environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the US. The programs, operated in collaboration with TerraCycle, help prevent these materials from ending up in landfills or waterways, where they could potentially impact aquatic environments and the human food supply.

Bausch + Lomb (NYSE/TSX: BLCO) reported strong Q3 2024 results with total revenue of $1.196 billion, up 19% year-over-year. The company achieved growth across all segments: Vision Care revenue reached $684 million (+6%), Surgical revenue hit $206 million (+11%), and Pharmaceuticals revenue grew to $306 million (+76%). GAAP Net Income was $4 million, compared to a net loss of $84 million in Q3 2023. Adjusted EBITDA increased to $212 million. Based on strong performance, the company raised its full-year 2024 revenue guidance to $4.725-$4.825 billion.